Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

Unicycive Therapeutics (Nasdaq: UNCY) resubmitted its NDA for oxylanthanum carbonate, an oral phosphate binder for CKD patients on dialysis. The resubmission includes new CMC data from a different vendor. The company expects FDA acceptance within 30 days and a PDUFA date 6 months from resubmission. Unicycive has $61.4M in cash, supporting operations into 2H 2027.

Original reporting
Published Sep 30, 2026, 1:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 3:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate — source image
Decision brief

The 30-second read

$UNCYNeutralMed
01

Why it matters

The NDA resubmission signals progress toward potential market entry, but the outcome hinges on FDA review and vendor inspections.

02

Market read

A positive FDA decision could drive a short‑term rally in UNCY; a negative outcome may trigger sell‑off.

03

What to watch

Cash runway to 2H 2027 reduces immediate financing risk, but the company remains dependent on a single product.

Relevance 7/10Novelty 8/10Timing: immediate

Background

Unicycive Therapeutics (NASDAQ: UNCY) is a clinical‑stage biotech focused on kidney disease treatments. Its lead candidate OLC is an oral phosphate binder.

Company-level read

Ticker impact

$UNCYNeutralHigh confidence
Context

Unicycive Therapeutics announced the resubmission of its NDA for oxylanthanum carbonate, expecting FDA acceptance within 30 days and a new PDUFA date six months out.

Expected impact

potential upside if FDA accepts the NDA; possible pressure if inspection issues arise

Evidence & confidence

Regulatory acceptance is a binary catalyst; the new vendor's clean inspection improves odds, but the original vendor's pending inspection creates uncertainty.

Market effects

May boost sentiment for kidney‑disease biotech peers if FDA moves favorably.

Limited to US biotech sector; no broader regional effect.

Low global impact beyond niche renal‑therapy market.

Counterpoint

Investors may short on the risk that the original vendor's inspection could delay approval.

Key entities

  • Unicycive Therapeutics

    Biotech developer of oxylanthanum carbonate.

  • FDA

    U.S. agency reviewing the NDA.

Related articles

MedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA

Unicycive Therapeutics announced the FDA accepted its resubmitted NDA for Oxylanthanum Carbonate (OLC), setting a PDUFA target action date of March 25, 2027. The resubmission addresses manufacturing deficiencies cited in a prior CRL. OLC is an investigational phosphate binder for CKD patients on dialysis, with potential market advantages due to its formulation.

$UNCYMed

FDA accepts Unicycive resubmission for kidney drug application

Unicycive Therapeutics (UNCY) announced the FDA accepted its resubmitted New Drug Application for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a target action date of March 25, 2027. The resubmission includes new manufacturing data from a different vendor, following a Complete Response Letter in June 2026. The company hopes for potential approval and does not know if the FDA will conduct a pre-approval inspection.

$UNCYMedAI 8/10

Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027

Unicycive Therapeutics (Nasdaq: UNCY) announced FDA acceptance of its resubmitted NDA for oxylanthanum carbonate, a treatment for hyperphosphatemia in chronic kidney disease patients. The FDA set a PDUFA date of March 25, 2027. The resubmission includes new manufacturing data. The company hopes for potential approval, pending FDA review and possible inspections.

$UNCYHighAI 8/10

Why is Unicycive Therapeutics stock rallying today?

Unicycive Therapeutics (UNCY) stock rose 3.5% after the FDA accepted its resubmission for oxylanthanum carbonate, a treatment for chronic kidney disease. The FDA set a March 2027 target action date. The resubmission includes new manufacturing data addressing prior deficiencies. The broader market also gained, supporting small-cap biotech stocks. The company faces ongoing legal action, capping gains.